Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07242963 · ClinicalTrials.gov registry record
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
A clinical trial of Medulloblastoma Recurrent and Medulloblastoma, Childhood, Recurrent, sponsored by Mohammad H. Abu Arja.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT07242963 is a study of Medulloblastoma Recurrent and Medulloblastoma, Childhood, Recurrent that is actively recruiting participants, run by Mohammad H. Abu Arja. The registered enrollment target is 300 participants, above the 113-participant average among 3 other Medulloblastoma Recurrent trials with a reported enrollment target (165% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07242963, a study of Medulloblastoma Recurrent and Medulloblastoma, Childhood, Recurrent, is actively recruiting participants, sponsored by Mohammad H. Abu Arja.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to create a biobank for patients diagnosed with Sonic Hedgehog Medulloblastoma at Baylor College of Medicine/Texas Children's Cancer Center. A biobank is a facility that stores and manages biological samples (such as blood, tissue, or DNA) from individuals, along with detailed health information, for use in medical research to study diseases and develop new treatments. The investigators are requesting participants' permission to add their information and samples to this biobank. Being in this research study is voluntary; it is the participant's choice. If the participant joins this study, they can still stop at any time. If the participant decides to participate, the investigators will review the participant's clinical medical records, demographics, treatment history, family history, and imaging. The investigators will also collect biological samples from the participant and the biological parents' buccal swabs (optional). The participation in this biobank will last about 5 years from the decision to participate. Why am I being asked to participate? The participant or their child is invited to participate in this study if the participant or their tumor may have a U1 mutation. U1 mutation is associated with an error in the gene that splices the tumor DNA, leading to random splicing that may increase the tumor mutation burden and generate novel tumor neoantigens (targets). Studying the U1 mutation will enable the investigator to design more effective therapies and guide future treatments for patients with relapsed or refractory sonic hedgehog medulloblastoma, thereby improving their outcomes and quality of life. Moreover, the investigators aim to determine whether germline mutations inherited from parents may increase the risk of medulloblastoma in their offspring. The participant will receive no direct benefit from their participation in this study. However, participation in this study may help the investigators better understand SHH
Conditions Studied
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2035-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07242963
The ClinicalTrials.gov registry entry for NCT07242963 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 113-participant average among 3 other Medulloblastoma Recurrent trials with a reported enrollment target (165% higher). The listed sponsor is Mohammad H. Abu Arja, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Medulloblastoma Recurrent appearing as the primary indexed condition, and to 0 interventions.
NCT07242963 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07242963 about?
NCT07242963 is a clinical study titled "Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study". The purpose of this study is to create a biobank for patients diagnosed with Sonic Hedgehog Medulloblastoma at Baylor College of Medicine/Texas Children's Cancer Center. A biobank is a facility that stores and manages biological samples (such as blood, tissue, or DNA) from individuals, along with de...
What is the current status of trial NCT07242963?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-09-30. Estimated completion is 2035-12-30.
What conditions does trial NCT07242963 study?
This clinical trial studies the following conditions: Medulloblastoma Recurrent, Medulloblastoma, Childhood, Recurrent, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype.
Who is sponsoring clinical trial NCT07242963?
This trial is sponsored by Mohammad H. Abu Arja, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07242963 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medulloblastoma Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
RECRUITING · NA
-
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
RECRUITING · Phase 2
-
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.